MDGL Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. (MDGL) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 49% planned / 51% discretionary
Largest single sale: $837.3K.
Where they traded
Last open-market purchase: November 6, 2026 .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| 3 fills | Buy | 76,140 | $384.32 | $29.3M | 2,040,682 | ||
| Kelley Shannon T | General Counsel | Sell 10b5-1 | 1,077 | $400.00 | $430.8K | 10,397 −9.4% of holding | |
| 2 fills | Buy | 15,666 | $367.71 | $5.8M | 1,964,542 | ||
| Sibold William John 10 fills | President and CEO | Sell 10b5-1 | 5,221 | $542.39 | $2.8M | 202,907 −2.5% of holding | |
| Sibold William John 14 fills | President and CEO | Sell | 6,362 | $535.59 | $3.4M | 209,198 −3% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.